financetom
TMO
financetom
/
Healthcare
/
TMO
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Thermo Fisher Scientific Inc.TMO
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally.

The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.

The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products.

Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research.

The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs.

Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Latest News >
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia
Mar 8, 2024
06:26 AM EST, 03/08/2024 (MT Newswires) -- Unicycive Therapeutics ( UNCY ) said Thursday it has completed patient enrollment in a pivotal clinical trial for Oxylanthanum Carbonate for the potential treatment of hyperphosphatemia in patients with chronic kidney disease. The company expects topline data from the trial in Q2. The primary endpoint for the trial will evaluate the tolerability of...
Enterprise Products Partners Kicks off Truck Loading Operations at Permian Terminal
Enterprise Products Partners Kicks off Truck Loading Operations at Permian Terminal
Mar 8, 2024
06:48 AM EST, 03/08/2024 (MT Newswires) -- Enterprise Products Partners ( EPD ) said late Thursday that truck loading operations have begun at its new Permian terminal in Gaines County, Texas. With this, the first phase of the company's Texas Western Products System is in service, it said in a statement. The facility features about 900,000 barrels of storage for...
Astera Labs eyes up to $4.5 bln valuation in US IPO
Astera Labs eyes up to $4.5 bln valuation in US IPO
Mar 8, 2024
March 8 (Reuters) - Astera Labs said on Friday it was eyeing a valuation of up to $4.51 billion in its U.S. initial public offering, as the chip firm looks to list amid a wave of enthusiasm for artificial intelligence. The company said it, along with some of its existing shareholders, is aiming to raise up to $534 million by...
AltaGas' Q4 Net Income Climbs YOY
AltaGas' Q4 Net Income Climbs YOY
Mar 8, 2024
06:48 AM EST, 03/08/2024 (MT Newswires) -- AltaGas Ltd. ( ATGFF ) on Friday reported fourth-quarter 2023 normalized net income of $214 million, or $0.75 per share, up from $189 million, or $0.67 per share, in the year-ago quarter. Normalized EBITDA for the quarter came in at $502 million, up from $454 million in the prior-year period. The company reiterated...
Copyright 2023-2025 - www.financetom.com All Rights Reserved